Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TREASURE Trial: Ketamine and VR for Treatment-Resistant Depression
NCT06781697Phase 3Recruiting
- Sponsor
- Sunnybrook Health Sciences Centre
- Start
- May 2026
- Primary completion
- Dec 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ketamine in treatment-resistant depression (TRD), sponsored by Sunnybrook Health Sciences Centre. Started May 2026; status: recruiting.
02
Drugs
ketamine
03
Conditions
treatment-resistant depression (TRD)
Beyond the preview
Go deeper on NCT06781697.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06781697.